Cross Country Healthcare, Inc. 2025 Annual Report: Key Takeaways for Investors

Overview

Cross Country Healthcare, Inc. (“Cross Country” or “the Company”) has released its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The report contains several developments and disclosures that investors and shareholders should carefully consider, as they may have implications for the Company’s share price and strategic direction.

Key Highlights and Price-Sensitive Developments

• Termination of the Aya Merger Agreement and Receipt of Termination Fee
  After market close on December 3, 2025, Cross Country received a formal notice of termination from Parent (Aya Holdings II Inc.) regarding the Aya Merger Agreement. The termination became effective December 4, 2025, as the merger was not consummated by the agreed end date. In accordance with the terms, Cross Country received a termination fee of \$20 million in cash from Parent. The failure to complete the merger and the associated cash infusion are material events that could significantly affect the company’s strategic outlook and valuation.
• Leadership Change: New President and CEO
  Effective December 14, 2025, John A. Martins, President and CEO, separated from the Company. Kevin C. Clark, the Company’s current Chairman of the Board, former CEO (January 16, 2019 – March 31, 2022), and co-founder, was appointed President and CEO effective December 15, 2025. Clark will continue as Chairman. This executive transition at a critical juncture could have material effects on company operations, culture, and investor confidence, especially given Clark’s previous tenure and leadership reputation.
• Financial Position and Shareholder Information
  As of February 17, 2026, the company had 32,318,741 shares of Common Stock outstanding. The market value of voting stock held by non-affiliates was \$393,124,934 (based on a closing price of \$13.05 per share as of June 30, 2025).
• Filings and Regulatory Status
  Cross Country is an accelerated filer (not a large accelerated filer, smaller reporting company, or emerging growth company). It has filed all required reports under the Exchange Act in the previous 12 months and attests to the effectiveness of its internal controls under Section 404(b) of Sarbanes-Oxley, as certified by its public accounting firm. No prior restatements or error corrections were indicated.
• Business Model, Investments, and Technology
  The Company is investing in recruitment and candidate nurturing tools, market analytics, mobile applications, self-serve capabilities, programmatic advertising, social media, and other technology infrastructure to support its healthcare staffing and education businesses. These investments are intended to enhance recruiting capabilities, operational execution, and customer experience—key drivers for future growth and market competitiveness.
• Geographic Markets and Operations
  All revenue in 2025, 2024, and 2023 was generated in the U.S., with significant back-office and IT operations in India. The Company notes that any material disruption to Indian-based operations could impact its ability to support customers and maintain key business processes.
• Corporate Social Responsibility (CSR)
  The Board regularly discusses CSR topics. Initiatives include advancing employability, being a preferred employer, partnering with customers, and driving positive social impacts. The Company provides health and wellness programs, a Compassion Fund for employees in hardship, and paid volunteer days.
• Risk Factors and Forward-Looking Statements
  The report identifies several business, economic, and operational risks:
  • Pandemics, epidemics, or public health crises could affect staffing and operations.
  • Economic downturns and credit market disruptions may impact liquidity and customer solvency.
  • Dependence on key management and risk of corporate employee turnover, especially given the recent CEO transition.
  • Significant operational reliance on technology systems and third-party vendors, with increasing cybersecurity threats and regulatory compliance costs (including U.S. and India operations).
  • Reputation risks, including those related to social media, CSR, and sustainability ratings, which could affect hiring and investor sentiment.
• Other Notable Items for Shareholders
  
  • No indication that the Company is a shell company.
  • Portions of the 2026 definitive proxy statement will be incorporated by reference into the 10-K.
  • No unresolved comments from the SEC were reported.

Potential Share Price Impact

The termination of the Aya Merger Agreement, the \$20 million cash termination fee, and the sudden CEO transition are all significant, potentially price-moving events. The strategic direction may shift under Kevin Clark’s renewed leadership, and the market may react to both the failed merger and the return of a founder-CEO. Additionally, the company’s continued investment in technology and the risks associated with international operations, regulatory compliance, and cybersecurity are crucial for shareholders to monitor.

Investors should also be attentive to the company’s ongoing operational risks (including its reliance on India-based operations and complex regulatory environments), as well as macroeconomic and market risks that could impact the demand for healthcare staffing services.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should review the full Cross Country Healthcare, Inc. Annual Report on Form 10-K and consult their own financial advisors before making any investment decisions. The information herein is based on the company’s SEC filings and may be subject to change or updates not reflected in this summary.

View CROSS COUNTRY HEALTHCARE INC Historical chart here